1 / 31

RECAP

RECAP. Addressing Exposure to Multiple Constituents that Elicit Noncarcinogenic Effects on the Same Target Organ/System. Assumption of Dose Additivity: Carcinogens. 1. Multiple chemicals: Risk T =  Risk i 2. Multiple exposure pathways:

makana
Download Presentation

RECAP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RECAP Addressing Exposure to MultipleConstituents that Elicit Noncarcinogenic Effects on the Same Target Organ/System

  2. Assumption of Dose Additivity: Carcinogens 1. Multiple chemicals: RiskT =  Riski 2. Multiple exposure pathways: Total Exposure Cancer Risk = Riskpathway1 + Riskpathway2 + … + Riskpathwayi RAGS-A EPA 1989

  3. Carcinogens and the RBCA Approach • A target risk level of 10-6 for individual chemicals and pathways generally will lead to a cumulative risk within the 10-6 to 10-4 range (SSG 1996) • Total Exposure Cancer Risk should be < 10-6 to 10-4 • Risk = EC1/RS1 + EC2/RS2 + … + ECi/Rsi X TR

  4. Assumption of Dose Additivity: Noncarcinogens 1. Multiple chemicals: Hazard Index = E1/RfD1 + E2/RfD2 + … + Ei/RfDi 2. Multiple exposure pathways: Total Hazard Index = HIpathway1 + HIpathway2 + … + HIpathwayi RAGS-A EPA 1989

  5. Assumption of Dose Additivity: Noncarcinogens • Simultaneous subthreshold exposures to multiple noncarcinogenic chemicals could result in an adverse health effect • Only applicable to noncarcinogenic chemicals that affect the same target organ/critical effect (RfD) RAGS-A EPA 1989

  6. Noncarcinogens and the RBCA Approach • No acceptable risk “range” • When multiple chemicals and/or pathways are present, target HQ should be adjusted so that the Total HI < 1.0 • Total HI = EC1/RS1 + EC2/RS2 + … + ECi/RSi

  7. MO-1 and MO-2 RS • Represent an acceptable exposure level for exposure to a single chemical via a single medium • Do not address additivity due to exposure to multiple chemicals or multiple exposure media • RS do address exposure via multiple pathways

  8. MO-1 and MO-2 RS • Risk-based RS must be adjusted to account for potential additive effects • Soilni, Soili, Soiles • GW1, GW2, GWes • Not applicable to SoilGW, Soilsat, GW3, Watersol, background levels, quantitation limits, MCLs, ceiling values

  9. MO-1: Accounting for Additivity • Modification of risk-based MO-1 RS: • group noncarcinogenic chemicals by target organ/critical effect

  10. MO-1: Accounting for Additivity 1. Identify the target organ/critical effect for each noncarcinogenic chemical (RfD) • http://www.epa.gov/iris/subst/index.html 2. Group the chemicals by target organ/critical effect 3. Divide the RS by the number of chemicals affecting the same target organ

  11. MO-1: Accounting for AdditivityExample Chemical Target Organ RS Adjusted RS A kidney 24 8 B kidney, liver 15 5 C CNS 10 D kidney 60 20 • Divide the RS for A, B, and D by 3 (kidney) (Same as calculating a RS using a THQ of 0.33)

  12. Additivity - MO-1 • If many noncarcinogenic COC are present: • Adjust NC RS to account for additivity • Compare adjusted NC RS to C RS and choose the lower of the two • NC RS presented in Appendix I Worksheets

  13. MO-2: Methods for Accounting for Additivity • Modification of risk-based MO-2 RS: • group by target organ/critical effect • site-specific apportionment of RS or THQ • calculation of a total HI for each target organ

  14. MO-2: Additivity Example:Site-specific apportionment COCTargetTHQRSTHQRSTHQRS A kidney 1.0 2 0.33 0.670.8 1.6 B kidney 1.0 90 0.33 300.1 9 C kidney 1.0 120 0.33 400.1 12 Total HI 3.0 1.0 1.0

  15. MO-2 Additivity Example:Calculation of a THI for Each Target Organ THIkidney = ECA/RSA + ECB/RSB + ECc/RSc where: EC = exposure concentration RS = RECAP Standard THIkidney = 1/1.6 + 0.5/9 + 3/12 = 0.93 • THI must be < 1.0

  16. MO-3B: Accounting for Additivity Modification of risk-based MO-3 RS: • site-specific apportionment of RS or THQ • calculation of a total HI for each target organ/effect • group by target organ/critical effect

  17. Additivity Exposure to Multiple Media • If there is exposure to chemicals via more than one medium, then RS must be modified to account for additivity • Applicable only to MO-2 and MO-3 • MO-2 Example: a receptor is being exposed to chemicals via drinking water (GW1 or GW2) and soil

  18. Additivity: TPH Fractions • Aliphatics C>6-C8 • Aliphatics C>8-C16 (C>8-C10, C>10-C12, C>12-C16) • Aliphatics C>16-C35 • Aromatics C>8-C16 (C>8-C10, C>10-C12, C>12-C16) • Aromatics C>16-C35

  19. Additivity: TPH • Additivity - TPH RS based on 10,000 cap • Do not adjust 10,000 cap • Identify risk-based value in Appendix I worksheets or calculate • Adjust risk-based RS to account for additive effects • If adjusted risk-based RS < 10,000, use risk-based RS • If adjusted risk-based RS > 10,000, use 10,000 cap

  20. Additivity: TPH FractionsExample • Soil: ethylbenzene, aliphatics C>8-C10, C>10-C12, C>12-C16 • Id of targets: ethylbenzene: liver, kidney, developmental aliphatics C>8-C10: liver, hematological system aliphatics C>10-C12: liver, hematological system aliphatics C>12-C16 : liver, hematological system • Additivity - Liver: ethylbenzene and aliphatics C>8-C16 • Adjustment factor: 2 NOT 4 C>8-C16

  21. Additivity: TPH FractionsExample (cont’d) • Adjustment of MO-1 Soilni: ethylbenzene: 1500/2 = 750 mg/kg aliphatics C>8-C10: 1100/2 = 550 mg/kg aliphatics C>10-C12: 2100/2 = 1050 mg/kg aliphatics C>12-C16 : 3100/2 = 1550 mg/kg

  22. MO-1 Additivity Example for SoilTable 2 - Gasoline release COCMO-1 SoilniTarget Organ/Effect benzene --- --- ethylbenzene 1500 liver, kidney, develop. toluene 690 liver, kid., CNS, nas.epi. xylene 12,000 activity, bw,mort. aliphatics C6-8 --- kidney aliphatics C8-10 1100 liver, hematol. sys. aliphatics C10-12 2100 liver, hematol. sys. aromatics C8-10 610 bw aromatics C10-12 1000 bw

  23. MO-1 Additivity Example for SoilTable 2 - Gasoline release Summarize by target organ: (3) liver: ethylbenzene, toluene, aliphatics C8-12 (3) kidney: ethylbenzene, toluene, aliphatics C6-8 (1) developmental: ethylbenzene (1) CNS: toluene (1) nasal epithelium: toluene (1) hyperactivity: xylene (2) bw: xylene, aromatics C8-12 (1) mortality: xylene (1) hematological system: aliphatics C8-12

  24. MO-1 Additivity Example for SoilTable 2 - Gasoline release COCAdjusted MO-1 Soilni benzene --- ethylbenzene 1500  3 = 500 (liver) toluene 690  3 = 230 (liver) xylene 12,000  2 = 6,000 (bw) aliphatics C6-8 --- aliphatics C8-10 1100  3 = 367 (liver) aliphatics C10-12 2100  3 = 700 (liver) aromatics C8-10 610 2 = 305 (bw) aromatics C10-12 1000  2 = 500 (bw)

  25. MO-1 Additivity Example for SoilTable 2 - Gasoline release Identification of the limiting soil RS: COCSoilniSoilGWDW*Soilsat benzene 1.5 4.8 900 ethylbenzene 500 29,040 230 toluene 230 52,800 520 xylene 6000 79,200 150 aliphatics C6-8 10,000 10,000 NA aliphatics C8-10 367 10,000 NA aliphatics C10-12 700 10,000 NA aromatics C8-10 305 10,000 NA aromatics C10-12 500 10,000 NA *based on a DF3 of 440

  26. MO-1 Additivity Example for GWTable 3 - Gasoline release COCMO-1 GW1Target Organ/Effect benzene --- --- ethylbenzene --- liver, kidney, develop. toluene --- liver, kid., CNS, nas.epi. xylene --- activity, bw, mortality aliphatics C6-8 32 kidney aliphatics C8-10 1.3 liver, hematol. sys. aliphatics C10-12 1.4 liver, hematol. sys. aromatics C8-10 0.34 bw aromatics C10-12 0.34 bw

  27. MO-1 Additivity Example for GWTable 3 - Gasoline release Summarize by target organ: (3) liver: ethylbenzene, toluene, aliphatics C8-12 (3) kidney: ethylbenzene, toluene, aliphatics C6-8 (1) developmental: ethylbenzene (1) CNS: toluene (1) nasal epithelium: toluene (1) hyperactivity: xylene (2) bw: xylene, aromatics C8-12 (1) mortality: xylene (1) hematological system: aliphatics C8-12

  28. MO-1 Additivity Example for GWTable 3 - Gasoline release COCAdjusted MO-1 GW1 benzene --- ethylbenzene --- toluene --- xylene --- aliphatics C6-8 32  3 = 11 (kidney) aliphatics C8-10 1.3  3 = 0.43 (liver) aliphatics C10-12 1.4  3 = 0.47 (liver) aromatics C8-10 0.34  2 = 0.17 (bw) aromatics C10-12 0.34  2 = 0.17 (bw)

  29. MO-1 Additivity Example for GWTable 3 - Gasoline release Identification of the limiting GW RS: COCGW1Watersol benzene 0.005 1800 ethylbenzene 0.7 170 toluene 1 530 xylene 10 160 aliphatics C6-8 11 NA aliphatics C8-10 0.43 NA aliphatics C10-12 0.47 NA aromatics C8-10 0.17 NA aromatics C10-12 0.17 NA

  30. Additivity: GW1 and GW2 • Include all NC COC when identifying targets • If no current exposure: • Adjust GW1 or GW2 RS based on NC effects • Do not adjust GW1 or GW2 RS based on MCL

  31. Additivity: GW1 and GW2 • If exposure is occurring: • Adjust GW1 or GW2 RS based on NC effects • For GW1 or GW2 RS based on MCL: 1. Calculate GW1 or GW2 RS for NC effects (Appendix I or J) 2. Adjust RS to account for additivity

More Related